Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OmniAb, Inc. (NASDAQ: OABI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to its official public record. OmniAb is a technology company that licenses discovery research platforms for antibody and peptide therapeutics, and its filings offer detail on how this business is structured and financed.
OmniAb’s current reports on Form 8-K include announcements of quarterly and year-to-date financial results, where the company breaks out revenue from license and milestone agreements, services, xPloration® instrument sales and related consumables, and royalties. These filings also discuss research and development and general and administrative expenses, other operating income, and net loss figures, giving context to the economics of its technology licensing and discovery services model.
Other 8-K filings describe material events such as securities purchase agreements for private placements of common stock. In these documents, OmniAb outlines the number of shares sold, purchase prices, intended use of proceeds for working capital and general corporate purposes, and related registration rights. Filings also confirm that OmniAb’s common stock is listed on The Nasdaq Global Market under the symbol OABI, with warrants listed on The Nasdaq Capital Market under OABIW, and that the company qualifies as an emerging growth company.
Shareholder-focused filings, including reports on annual meetings, provide voting results for director elections and ratification of the independent registered public accounting firm. Together, these SEC documents help investors analyze governance, capital structure, financing transactions, and the financial performance of OmniAb’s antibody discovery technology business. Stock Titan enhances this information with AI-powered summaries that explain key points from forms such as 10-K, 10-Q, 8-K, and ownership reports, helping readers quickly understand the implications of each filing.
OmniAb, Inc. director Philip J. Gotwals reported an exercise of restricted stock units into common shares. On April 21, 2026, 13,333 Restricted Stock Units converted into 13,333 shares of Common Stock at a stated price of $0.0000 per share.
Following the transaction, he directly holds 13,333 shares of Common Stock and 46,667 Restricted Stock Units. The RSUs vest in three substantially equal annual installments beginning April 21, 2026, subject to his continued service with OmniAb through each vesting date.
OmniAb, Inc. director Steven C. Crouse acquired 13,333 shares of Common Stock through the exercise of Restricted Stock Units at a stated price of $0.00 per share. Following the transaction, he directly holds 13,333 Common shares and 46,667 Restricted Stock Units.
The 13,333 Restricted Stock Units referenced in the filing vest in three substantially equal annual installments beginning on April 21, 2026, subject to Crouse’s continued service. Each Restricted Stock Unit represents a contingent right to receive one share of OmniAb’s Common Stock.
The issuer reported a Form 144 notice for the proposed sale of 13,542 shares of Common Stock classified as Restricted Stock and labeled Compensation. The filing lists two prior sales in February: 6,828 and 9,301 shares.
OmniAb, Inc. President and CEO Matthew W. Foehr reported routine equity compensation activity. On April 7, 2026, 36,459 Restricted Stock Units vested and were converted into the same number of OmniAb common shares at no exercise price. To satisfy tax withholding obligations tied to this vesting, 19,244 shares of common stock were sold in mandated “sell-to-cover” transactions at a weighted average price of $1.49 per share, rather than at Foehr’s discretion. Following these transactions, Foehr directly holds 4,420,492 shares of OmniAb common stock and 309,376 RSUs, indicating that the sale represents a small portion of his overall equity position.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for proposed sale of 36,459 shares of restricted common stock on 04/07/2026, listed as compensation securities. The filing also records prior sales of 20,754 shares on 02/17/2026 and 30,843 shares on 02/18/2026.
OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported routine equity compensation activity. On April 7, 2026, 13,542 Restricted Stock Units vested, converting into the same number of common shares at no cost. To cover tax withholding on this vesting, 6,913 common shares were sold in a mandated sell-to-cover transaction at a weighted average price of $1.49 per share, rather than as a discretionary sale. After these events, he directly holds 261,483 shares of OmniAb common stock, reflecting prior transfers including 13,997 shares delivered to an ex-spouse under a domestic relations order.
OmniAb, Inc. Chief Legal Officer Charles S. Berkman reported routine equity compensation activity. On April 7, 2026, 13,542 Restricted Stock Units vested, converting into the same number of common shares at no exercise price. To satisfy tax withholding obligations under OmniAb’s equity incentive plans, 7,157 common shares were sold in a mandated “sell-to-cover” transaction at a weighted-average price of $1.49 per share, rather than as a discretionary trade. Following these transactions, Berkman directly holds 399,085 shares of OmniAb common stock and 111,042 RSUs, indicating that only a small portion of his position was sold.
OABI filed a Rule 144 notice to sell 13,542 shares of common stock. The filing lists these as restricted stock issued for compensation with an intended sale date of 04/07/2026. The notice also reports prior sales of 6,990 shares on 02/17/2026 and 9,673 shares on 02/18/2026.
OmniAb, Inc. provides a licensing-based antibody discovery platform used by pharmaceutical, biotech and academic partners to develop next‑generation therapeutics. Its transgenic animal technologies, AI‑driven screening and ion channel expertise are designed to generate fully human, high‑quality antibody candidates across many disease areas.
OmniAb’s business model centers on platform access fees, research services, milestones and downstream royalties on partner products. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 clinical programs, two antibodies under regulatory review and three approved, partner‑commercialized products.
OmniAb, Inc. reported weaker 2025 results but outlined growth plans and tighter cost control. Full-year 2025 revenue was $18.7 million, down from $26.4 million in 2024, mainly due to lower license, milestone and service revenue, partly offset by new xPloration and higher royalty revenue. The company posted a 2025 net loss of $64.8 million, or $0.57 per share, slightly higher than the prior year’s $62.0 million loss.
Research and development expense fell to $47.8 million and general and administrative expense to $29.2 million, helped by lower headcount, share-based compensation and legacy ion channel spending, though results included a $3.9 million impairment. OmniAb ended 2025 with $54.0 million in cash, cash equivalents and short-term investments.
For 2026, OmniAb guides to $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses, with non‑GAAP cash costs of $50–$55 million, and expects year-end cash of $30–$35 million and an effective tax rate of approximately 0%. The company highlights 107 active partners, 407 active programs, the launch of its OmniUltra transgenic chicken platform, and multiple partner programs progressing through clinical development.